Sipuleucel-T: immunotherapy for advanced prostate cancer

leucel-T: immunotherapy for advanced prostate cancer Review (3284) Total Article Views Authors: Olson BM, McNeel DG Published Date May 2011 Volume 2011:3 Pages 49 - 60 DOI: http://dx.doi.org/10.2147/RRU.S13069 Brian M Olson, Douglas G McNeel University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA Abstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.